TRIP13 and cancer: Two recent reports found that knocking-out TRIP13 from human cancer cell lines or introducing mutations in Pch2, the TRIP13 orthologue in C. elegans, resulted mitotic checkpoint activation defects, arguing that TRIP13 is also involved in establishing or maintaining the mitotic checkpoint [206,207].